Relationship between PPARγ Pro12Ala gene polymorphism and type 2 diabetic nephropathy risk in Asian population: Results from a meta-analysis

Journal of Receptors and Signal Transduction

Volumn 34, Issue 2, 2014, Pages 131-136

  Liu, Guohui ^a   Zhou, Tian Biao ^b   Jiang, Zongpei ^b   Zheng, Dongwen ^a   Yuan, Fei ^a   Li, Yi ^a   Hu, Haoqiang ^a   Chen, Zijun ^a  

^a Dong Guan Municipal People's Hospital   (China)

^b THE SIXTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Gene polymorphism; Meta analysis; PPAR ; Pro12Ala; Type 2 diabetic nephropathy

Indexed keywords

ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE;

ARTICLE; ASIAN; COCHRANE LIBRARY; DATA BASE; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; POPULATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SAMPLE SIZE; SENSITIVITY ANALYSIS;

ASIA; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 84897876545     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2013.864678     Document Type: Article

References (29)

1. Zhou TB, Drummen GP, Jiang ZP, et al. Association of peroxisome proliferator-activated receptors/retinoic acid receptors with renal diseases. J Recept Signal Transduct Res 2013. [Epub ahead of print]. doi: 10.3109/10799893.2013.838786.
2. Ma JJ, Zhang T, Fang N, et al. Establishment of a cell-based drug screening model for identifying agonists of human peroxisome proliferator-activated receptor gamma (PPARgamma). J Pharm Pharmacol 2012;64:719-26.
3. Zhou TB, Ou C, Luo CP, Xu HL. Protective effects of PPARgamma agonist in glomerulosclerosis rats induced by adriamycin. Ren Fail 2012,34:940-1.
4. Okunuki Y, Usui Y, Nakagawa H, et al. Peroxisome proliferatoractivated receptor-gamma agonist pioglitazone suppresses experimental autoimmune uveitis. Exp Eye Res 2013;116C:291-7.
5. Jesse CR, Bortolatto CF, Wilhelm EA, et al. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone protects against cisplatin-induced renal damage in mice. J Appl Toxicol 2012. [Epub ahead of print]. doi: 10.1002/jat.2818.
6. Ramirez A, Ballard EN, Roman J. TGFbeta1 controls PPARgamma expression, transcriptional potential, and activity, in part, through Smad3 signaling in murine lung fibroblasts. PPAR Res 2012;2012: 375876.
7. Eid S, Abou-Kheir W, Sabra R, et al. Involvement of renal cytochromes P450 and arachidonic acid metabolites in diabetic nephropathy. J Biol Regul Homeost Agents 2013;27: 693-703.
8. Mooyaart AL. Genetic associations in diabetic nephropathy. Clin Exp Nephrol 2013. [Epub ahead of print]. doi: 10.1007/ s10157-013-0874-9.
9. Khajehdehi P, Pakfetrat M, Javidnia K, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol 2011;45:365-70.
10. Zhou TB, Yin SS. Association of matrix metalloproteinase-9 level with the risk of renal involvement for Henoch-Schonlein purpura in children. Ren Fail 2013;35:425-9.
11. Zhou TB, Yin SS, Liang R. A meta-analysis of the association between angiotensin-converting enzyme insertion/deletion gene polymorphism and end-stage renal disease risk in IgA nephropathy patients. J Renin Angiotensin Aldosterone Syst 2013;14:235-41.
12. Cheng HY, You HY, Zhou TB. Relationship between GSTM1/ GSTT1 null genotypes and renal cell carcinoma risk: a metaanalysis. Ren Fail 2012;34:1052-7.
13. Zhou TB, Qin YH, Xu HL. Association of apoE gene expression and its gene polymorphism with nephrotic syndrome susceptibility: a meta-analysis of experimental and human studies. Mol Biol Rep 2012;39:9347-54.
14. Zhou TB, Yin SS. Association of endothelial nitric oxide synthase Glu298Asp gene polymorphism with the risk of end-stage renal disease. Ren Fail 2013;35:573-8.
15. Zhou TB, Yin SS, Jiang ZP. Association of angiotensin II type-1 receptor A1166C gene polymorphism with the susceptibility of end-stage renal disease. J Recept Signal Transduct Res 2013;33: 325-31.
16. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997;315: 629-34.
18. Erdogan M, Karadeniz M, Eroglu Z, et al. The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract 2007;78: 355-9.
19. Liu L, Zheng T, Wang F, et al. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 2010;33: 144-9.
20. Maeda A, Gohda T, Funabiki K, et al. Peroxisome proliferatoractivated receptor gamma gene polymorphism is associated with serum triglyceride levels and body mass index in Japanese type 2 diabetic patients. J Clin Lab Anal 2004;18:317-21.
21. Mori H, Ikegami H, Kawaguchi Y, et al. The Pro12 -4Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 2001;50:891-4.
22. Wu LS, Hsieh CH, Pei D, et al. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant 2009;24:3360-6.
23. Zhang H, Zhu S, Chen J, et al. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care 2012;35:1388-93.
24. Wei F, Wang J, Wang C, et al. The relationship between the pro12Ala polymorphism in PPAR-g2 gene and diabetic nephropathy in Baotou. Chinese J Diabetes 2008;16:679-80.
25. Zhu W, Ji Y, Bu L, Yang Q. The correlativity study of peroxisome proliferator activated receptor g2 gene polymorphism with susceptibility of diabetic nephropathy in type 2 diabetes mellitus. J Radioimmunol 2011;24:296-8.
26. Li L, Liu L, Zheng T, et al. Peroxisome proliferator activated receptor g2 gene P12A polymorphism and type 2 diabetic nephropathy in Han population in Shanghai. J Shanghai Jiaotong Univ 2008;28:376-9.
27. Wu S. Study on the relationship of polymorphism of PPAR-g2 and type 2 diabetes and diabetic nephropathy [dissertation]. Tianjin: Tianjin Medical University; 2004.
28. Wang L, Teng Z, Cai S, et al. The association between the PPARgamma2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects. Diagn Pathol 2013;8:118.
29. De Cosmo S, Prudente S, Lamacchia O, et al. PPARgamma2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. Nephrol Dial Transplant 2011;26:4011-6.